EPISODE · Jul 18, 2018 · 6 MIN
Recently Approved Drugs: Lutetium Lu 177 dotatate for treatment of GEP-NETs
from ASCO Education
Dr. Jonathan Strosberg, section chief of the Neuroendocrine Tumor Division of the Moffitt Cancer Center, discusses the recent FDA approval of Lutetium Lu 177 dotatate for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Embed this episode
NOW PLAYING
Recently Approved Drugs: Lutetium Lu 177 dotatate for treatment of GEP-NETs
0:00
6:59
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of ASCO Education?
This episode is 6 minutes long.
When was this ASCO Education episode published?
This episode was published on July 18, 2018.
Can I download this ASCO Education episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!